literature

HBV mutation literature information.

Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.

PMID: 17224847 2007 Journal of acquired immune deficiency syndromes (1999)

Abstract: The dual L180M + M204V/I mutant was the predominant resistance pattern, although a triple rt173V + 180M + 204V, which acts as a vaccine escape mutant, was found in 1 individual.

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

PMID: 17438047 2007 Antimicrobial agents and chemotherapy

Abstract: Collectively, these results suggest that coselection of rtL80V/I and rtM204I/V occurs because the former compensates for the loss of replication efficiency associated with the acquisition of LMV resistance, particularly in the case of rtM204I.

Abstract: Coselection of rtL80V/I occurred in 46% of isolates in which LMV resistance was attributable to rtM204I but only 9% of those in which resistance was attributable to rtM204V.

Abstract: Mutations that result in the replacement of the methionine at position 204 of the deoxynucleoside triphosph

Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.

PMID: 17567633 2007 The Journal of antimicrobial chemotherapy

Abstract: rtA181S without rtM204I/V was found in one patient.

Abstract: All but three patients had baseline rtM204I/V substitutions associated with rtL180M in 23, rtL80I/V in 14, rtV173L in 4, rtT184S in 3, rtQ215S in 2 and rtA181S in 2 cases.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

PMID: 17854034 2007 Journal of medical virology

Abstract: Baseline characteristics, alanine aminotransferase (ALT) levels, and HBV DNA levels within 6 months after the emergence of YMDD variants did not differ significantly between patients with rtM204I alone and those with rtL180M/rtM204V.

Abstract: Between months 5 and 33 of therapy, mutations from methionine to isoleucine at rt204 (rtM204I) were detected in 18 patients, and mutations from methionine to valine at rt204 (rtM204V) were detected in 12.

Abstract: During long term follow-up, the addition of

Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

PMID: 17913933 2007 Journal of clinical microbiology

Abstract: In all 20 patients, the mutation occurred in the YMDD motif at reverse transcriptase position 204 (rt204; M204V/I) either with or without the compensatory mutation at position rt180 (L180M).

Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates.

PMID: 18036224 2007 BMC microbiology

Table: M204I

Dynamics of hepatitis B virus resistance to lamivudine.

PMID: 16378967 2006 Journal of virology

Abstract: Virological breakthrough was preceded by 2 to 4 months by the emergence of quasispecies variants bearing amino acid substitutions at RT position 204, i.e., within the YMDD catalytic motif (rtM204V/I).

[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].

PMID: 16448607 2006 Gastroenterologia y hepatologia

Abstract: We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected.

Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.

PMID: 16539393 2006 Journal of medicinal chemistry

Abstract: These compounds were also found to retain sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and double mutations (L180M/M204V).

Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.

PMID: 16611191 2006 Journal of viral hepatitis

Abstract: In conclusion, switching to ADV monotherapy after emergence of LAM-resistant rtM204 I/V is effective and safe in cirrhotic patients, even in those with hepatic decompensation.

Abstract: Switching to adefovir (ADV) monotherapy is effective in patients with lamivudine (LAM)-resistant hepatitis B virus (HBV) mutations (rtM204 I/V).

Abstract: The clinical, biochemical and virological responses were compared between ADV monotherapy in 18 cirrhotic patients and ADV add-on LAM therapy in 10 comparable cirrhotic patients with LAM-resistant rtM204 I/V.

Browser Board

Co-occurred Entities

Filtrator